Monarch Partners Asset Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Monarch Partners Asset Management’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$2.23M	Buy	113,788 +27,003	+31%	+$497K	0.66%	70
2022 Q3	$1.39M	Buy	+86,785	New	+$1.35M	0.42%	115
2020 Q4	–	Sell	-26,090	Closed	-$596K	–	206
2020 Q3	$596K	Buy	26,090 +8,410	+48%	+$207K	0.13%	141
2020 Q2	$370K	Buy	+17,680	New	+$319K	0.09%	153
2018 Q4	–	Sell	-11,897	Closed	-$293K	–	203
2018 Q3	$293K	Sell	11,897 -3,085	-21%	-$66.9K	0.03%	190
2018 Q2	$294K	Hold	14,982	–	–	0.03%	187
2018 Q1	$281K	Buy	+14,982	New	+$244K	0.03%	187

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Monarch Partners Asset Management's RCKT Position: Q4 2022 in Review

Monarch Partners Asset Management increased its Rocket Pharmaceuticals (RCKT) stake by 31% in Q4 2022, buying an estimated $497K and bringing the position to 113,788 shares worth $2.23M. The position accounts for 0.66% of the portfolio, ranked #70.

Monarch Partners Asset Management first reported a position in RCKT in Q1 2018 and has held it in 7 quarters since. 167 funds tracked by Wall St. Rank hold RCKT as of Q4 2022.

Monarch Partners Asset Management held 113,788 shares of Rocket Pharmaceuticals worth $2.23M as of Q4 2022.
Monarch Partners Asset Management bought 27,003 Rocket Pharmaceuticals shares in Q4 2022, an estimated $497K.
Rocket Pharmaceuticals made up 0.66% of Monarch Partners Asset Management's portfolio in Q4 2022, its #70 holding.
Monarch Partners Asset Management first reported a position in Rocket Pharmaceuticals in Q1 2018 and has held it in 7 quarters since.
167 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2022.

Based on Monarch Partners Asset Management's 13F filing for Q4 2022, filed 2 Feb 2023.